Ligand Pharmaceuticals Inc (LGND): who owns it and who trades it
As of Nov 16, 2026, LGND insiders reported 151 open-market sales worth $36.5M and no purchases in the last 12 months, with 70% of the sale value made under pre-set 10b5-1 plans. The largest seller was Octavio Espinoza (CFO), with $13M. 5 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Ligand Pharmaceuticals
From the latest filingsOverall: more buying than selling. Insiders mostly sold. Funds, famous investors and Congress mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns LGND
414 funds and institutions reported LGND shares worth $7.2B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is BlackRock, Inc. with 15.5%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 3.10M | 15.47% | $980M | +5% |
| Invesco Ltd. | 1.20M | 6.00% | $380M | +46% |
| Vanguard Portfolio Management LLC | 1.14M | 5.68% | $360M | +3% |
| Jupiter Topco LLC | 1.04M | 5.19% | $329M | – |
| Vanguard Capital Management LLC | 870,950 | 4.35% | $275M | +3% |
| State Street Corp | 826,539 | 4.12% | $261M | +6% |
| FMR LLC (Fidelity) | 762,827 | 3.81% | $241M | +28% |
| Franklin Resources Inc | 752,044 | 3.75% | $238M | +31% |
| Congress Asset Management Co | 659,911 | 3.29% | $209M | +31% |
| Geode Capital Management, LLC | 589,020 | 2.94% | $186M | +5% |
| Nomura Asset Management International Inc. | 568,371 | 2.84% | $180M | -1% |
| Chicago Capital, LLC | 553,435 | 2.76% | $175M | -1% |
| Stephens Investment Management Group LLC | 475,609 | 2.37% | $150M | -4% |
| Dimensional Fund Advisors LP | 429,314 | 2.14% | $136M | +1% |
| Massachusetts Financial Services Co | 375,762 | 1.87% | $119M | -9% |
| Goldman Sachs Group Inc | 323,245 | 1.61% | $102M | -15% |
| Loomis Sayles & Co L P | 291,805 | 1.46% | $92.2M | -17% |
| Rice Hall James & Associates, LLC | 270,052 | 1.35% | $85.4M | -5% |
| Ranger Investment Management, L.P. | 257,596 | 1.29% | $81.4M | -4% |
| Northern Trust Corp | 257,389 | 1.28% | $81.4M | +1% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, LGND insiders reported $0 of open-market purchases and $36.5M of sales. 70% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 12, 2026 | John W Kozarich | Director | Sale plan | 500 | $325.00 | $162K | Form 4 |
| Nov 12, 2026 | Martine Zimmermann | Director | Sale | 2,000 | $318.17 | $636K | Form 4 |
| Nov 10, 2026 | Jason Aryeh | Director | Sale | 500 | $319.99 | $160K | Form 4 |
| Nov 10, 2026 | Jason Aryeh | Director | Sale | 844 | $320.00 | $270K | Form 4 |
| Nov 10, 2026 | Jason Aryeh | Director | Sale | 646 | $320.00 | $207K | Form 4 |
| Nov 10, 2026 | Jason Aryeh | Director | Sale | 10 | $320.02 | $3.2K | Form 4 |
| Nov 10, 2026 | Jason Aryeh | Director | Sale | 500 | $320.10 | $160K | Form 4 |
| Nov 10, 2026 | Jason Aryeh | Director | Sale | 500 | $320.20 | $160K | Form 4 |
| Nov 4, 2026 | Jason Aryeh | Director | Sale | 282 | $319.99 | $90.2K | Form 4 |
| Nov 2, 2026 | Andrew Reardon | CLO & Secretary | Sale plan | 283 | $307.39 | $87K | Form 4 |
| Nov 2, 2026 | Andrew Reardon | CLO & Secretary | Sale plan | 708 | $308.43 | $218K | Form 4 |
| Nov 2, 2026 | Andrew Reardon | CLO & Secretary | Sale plan | 522 | $309.91 | $162K | Form 4 |
| Nov 2, 2026 | Andrew Reardon | CLO & Secretary | Sale plan | 490 | $310.61 | $152K | Form 4 |
| Nov 2, 2026 | Andrew Reardon | CLO & Secretary | Sale plan | 520 | $311.72 | $162K | Form 4 |
| Nov 2, 2026 | Andrew Reardon | CLO & Secretary | Sale plan | 634 | $312.85 | $198K | Form 4 |
| Nov 2, 2026 | Andrew Reardon | CLO & Secretary | Sale plan | 403 | $313.75 | $126K | Form 4 |
| Nov 2, 2026 | Andrew Reardon | CLO & Secretary | Sale plan | 80 | $314.58 | $25.2K | Form 4 |
| Nov 2, 2026 | Andrew Reardon | CLO & Secretary | Sale plan | 280 | $317.91 | $89K | Form 4 |
| Nov 2, 2026 | Andrew Reardon | CLO & Secretary | Sale plan | 440 | $318.73 | $140K | Form 4 |
| Nov 2, 2026 | Andrew Reardon | CLO & Secretary | Sale plan | 320 | $319.97 | $102K | Form 4 |
| Nov 2, 2026 | Andrew Reardon | CLO & Secretary | Sale plan | 200 | $321.44 | $64.3K | Form 4 |
| Nov 2, 2026 | Andrew Reardon | CLO & Secretary | Sale plan | 120 | $323.14 | $38.8K | Form 4 |
| Nov 2, 2026 | Jason Aryeh | Director | Sale | 700 | $320.43 | $224K | Form 4 |
| Oct 30, 2026 | Jason Aryeh | Director | Sale | 50 | $317.74 | $15.9K | Form 4 |
| Oct 30, 2026 | Jason Aryeh | Director | Sale | 50 | $318.23 | $15.9K | Form 4 |
| Oct 30, 2026 | Jason Aryeh | Director | Sale | 52 | $320.24 | $16.7K | Form 4 |
| Oct 30, 2026 | Jason Aryeh | Director | Sale | 1,209 | $320.42 | $387K | Form 4 |
| Oct 30, 2026 | Jason Aryeh | Director | Sale | 50 | $320.49 | $16K | Form 4 |
| Oct 2, 2026 | Andrew Reardon | CLO & Secretary | Sale plan | 833 | $302.51 | $252K | Form 4 |
| Oct 2, 2026 | Andrew Reardon | CLO & Secretary | Sale plan | 1,976 | $303.54 | $600K | Form 4 |
| Oct 2, 2026 | Andrew Reardon | CLO & Secretary | Sale plan | 1,535 | $304.52 | $467K | Form 4 |
| Oct 2, 2026 | Andrew Reardon | CLO & Secretary | Sale plan | 404 | $306.18 | $124K | Form 4 |
| Oct 2, 2026 | Andrew Reardon | CLO & Secretary | Sale plan | 235 | $307.19 | $72.2K | Form 4 |
| Oct 2, 2026 | Andrew Reardon | CLO & Secretary | Sale plan | 17 | $307.74 | $5.2K | Form 4 |
| Sep 10, 2026 | Martine Zimmermann | Director | Sale | 1,200 | $285.00 | $342K | Form 4 |
| Sep 3, 2026 | Andrew Reardon | CLO & Secretary | Sale plan | 385 | $287.53 | $111K | Form 4 |
| Sep 3, 2026 | Andrew Reardon | CLO & Secretary | Sale plan | 1,800 | $285.17 | $513K | Form 4 |
| Sep 3, 2026 | Andrew Reardon | CLO & Secretary | Sale plan | 2,115 | $286.36 | $606K | Form 4 |
| Sep 3, 2026 | Andrew Reardon | CLO & Secretary | Sale plan | 300 | $283.99 | $85.2K | Form 4 |
| Sep 3, 2026 | Andrew Reardon | CLO & Secretary | Sale plan | 400 | $288.98 | $116K | Form 4 |
| Aug 12, 2026 | Octavio Espinoza | CFO | Sale plan | 31,641 | $292.07 | $9.2M | Form 4 |
| Aug 12, 2026 | Jason Haas | Director | Sale | 7,138 | $292.81 | $2.1M | Form 4 |
| Aug 3, 2026 | Andrew Reardon | CLO & Secretary | Sale plan | 200 | $290.60 | $58.1K | Form 4 |
| Aug 3, 2026 | Andrew Reardon | CLO & Secretary | Sale plan | 991 | $291.71 | $289K | Form 4 |
| Aug 3, 2026 | Andrew Reardon | CLO & Secretary | Sale plan | 409 | $292.82 | $120K | Form 4 |
| Aug 3, 2026 | Andrew Reardon | CLO & Secretary | Sale plan | 105 | $284.14 | $29.8K | Form 4 |
| Aug 3, 2026 | Andrew Reardon | CLO & Secretary | Sale plan | 33 | $284.55 | $9.4K | Form 4 |
| Aug 3, 2026 | Andrew Reardon | CLO & Secretary | Sale plan | 157 | $285.74 | $44.9K | Form 4 |
| Aug 3, 2026 | Andrew Reardon | CLO & Secretary | Sale plan | 1,032 | $286.80 | $296K | Form 4 |
| Aug 3, 2026 | Andrew Reardon | CLO & Secretary | Sale plan | 1,214 | $287.77 | $349K | Form 4 |
| Aug 3, 2026 | Andrew Reardon | CLO & Secretary | Sale plan | 356 | $288.75 | $103K | Form 4 |
| Aug 3, 2026 | Andrew Reardon | CLO & Secretary | Sale plan | 503 | $289.80 | $146K | Form 4 |
| Jul 1, 2026 | Andrew Reardon | CLO & Secretary | Sale plan | 600 | $317.15 | $190K | Form 4 |
| Jul 1, 2026 | Andrew Reardon | CLO & Secretary | Sale plan | 900 | $315.78 | $284K | Form 4 |
| Jul 1, 2026 | Andrew Reardon | CLO & Secretary | Sale plan | 100 | $314.58 | $31.5K | Form 4 |
| Jul 1, 2026 | Andrew Reardon | CLO & Secretary | Sale plan | 700 | $313.46 | $219K | Form 4 |
| Jul 1, 2026 | Andrew Reardon | CLO & Secretary | Sale plan | 1,081 | $312.28 | $338K | Form 4 |
| Jul 1, 2026 | Andrew Reardon | CLO & Secretary | Sale plan | 1,119 | $311.72 | $349K | Form 4 |
| Jul 1, 2026 | Andrew Reardon | CLO & Secretary | Sale plan | 104 | $310.20 | $32.3K | Form 4 |
| Jul 1, 2026 | Andrew Reardon | CLO & Secretary | Sale plan | 396 | $308.99 | $122K | Form 4 |
| Jun 16, 2026 | Stephen L Sabba | Director | Sale | 2,145 | $254.00 | $545K | Form 4 |
| Jun 12, 2026 | Jason Haas | Director | Sale | 3,461 | $256.08 | $886K | Form 4 |
| Jun 12, 2026 | Jason Haas | Director | Sale | 3,000 | $255.01 | $765K | Form 4 |
| Jun 11, 2026 | Jason Aryeh | Director | Sale | 4,500 | $250.00 | $1.1M | Form 4 |
| Jun 10, 2026 | Jason Aryeh | Director | Sale | 500 | $250.00 | $125K | Form 4 |
| Jun 10, 2026 | John L Lamattina | Director | Sale | 257 | $247.22 | $63.5K | Form 4 |
| Jun 10, 2026 | John L Lamattina | Director | Sale | 3,405 | $251.62 | $857K | Form 4 |
| Jun 10, 2026 | John L Lamattina | Director | Sale | 697 | $249.53 | $174K | Form 4 |
| Jun 10, 2026 | John L Lamattina | Director | Sale | 232 | $248.11 | $57.6K | Form 4 |
| Jun 1, 2026 | Andrew Reardon | CLO & Secretary | Sale plan | 491 | $223.95 | $110K | Form 4 |
| Jun 1, 2026 | Andrew Reardon | CLO & Secretary | Sale plan | 677 | $225.20 | $152K | Form 4 |
| Jun 1, 2026 | Andrew Reardon | CLO & Secretary | Sale plan | 1,432 | $225.97 | $324K | Form 4 |
| Jun 1, 2026 | Andrew Reardon | CLO & Secretary | Sale plan | 400 | $226.78 | $90.7K | Form 4 |
| Jun 1, 2026 | Andrew Reardon | CLO & Secretary | Sale plan | 584 | $228.57 | $133K | Form 4 |
| Jun 1, 2026 | Andrew Reardon | CLO & Secretary | Sale plan | 200 | $230.41 | $46.1K | Form 4 |
| Jun 1, 2026 | Andrew Reardon | CLO & Secretary | Sale plan | 1,216 | $229.47 | $279K | Form 4 |
| May 13, 2026 | John W Kozarich | Director | Sale plan | 1,575 | $223.50 | $352K | Form 4 |
| May 12, 2026 | John W Kozarich | Director | Sale plan | 459 | $224.00 | $103K | Form 4 |
| May 1, 2026 | John W Kozarich | Director | Sale plan | 1 | $229.87 | $230 | Form 4 |
| May 1, 2026 | John W Kozarich | Director | Sale plan | 165 | $231.87 | $38.3K | Form 4 |
| May 1, 2026 | John W Kozarich | Director | Sale plan | 105 | $232.57 | $24.4K | Form 4 |
| May 1, 2026 | John W Kozarich | Director | Sale plan | 116 | $234.09 | $27.2K | Form 4 |
| May 1, 2026 | John W Kozarich | Director | Sale plan | 80 | $227.37 | $18.2K | Form 4 |
| May 1, 2026 | Andrew Reardon | CLO & Secretary | Sale plan | 98 | $229.71 | $22.5K | Form 4 |
| May 1, 2026 | Andrew Reardon | CLO & Secretary | Sale plan | 370 | $230.87 | $85.4K | Form 4 |
| May 1, 2026 | Andrew Reardon | CLO & Secretary | Sale plan | 1,420 | $232.92 | $331K | Form 4 |
| May 1, 2026 | Andrew Reardon | CLO & Secretary | Sale plan | 800 | $234.02 | $187K | Form 4 |
| May 1, 2026 | Andrew Reardon | CLO & Secretary | Sale plan | 932 | $228.75 | $213K | Form 4 |
| May 1, 2026 | Andrew Reardon | CLO & Secretary | Sale plan | 600 | $227.45 | $136K | Form 4 |
| May 1, 2026 | Andrew Reardon | CLO & Secretary | Sale plan | 780 | $232.04 | $181K | Form 4 |
| Apr 1, 2026 | John W Kozarich | Director | Sale plan | 43 | $202.91 | $8.7K | Form 4 |
| Apr 1, 2026 | John W Kozarich | Director | Sale plan | 79 | $202.42 | $16K | Form 4 |
| Apr 1, 2026 | John W Kozarich | Director | Sale plan | 40 | $201.24 | $8K | Form 4 |
| Apr 1, 2026 | John W Kozarich | Director | Sale plan | 146 | $199.97 | $29.2K | Form 4 |
| Apr 1, 2026 | John W Kozarich | Director | Sale plan | 159 | $204.26 | $32.5K | Form 4 |
| Apr 1, 2026 | Andrew Reardon | CLO & Secretary | Sale plan | 460 | $198.85 | $91.5K | Form 4 |
| Apr 1, 2026 | Andrew Reardon | CLO & Secretary | Sale plan | 1,302 | $199.72 | $260K | Form 4 |
| Apr 1, 2026 | Andrew Reardon | CLO & Secretary | Sale plan | 1,238 | $200.94 | $249K | Form 4 |
| Apr 1, 2026 | Andrew Reardon | CLO & Secretary | Sale plan | 700 | $201.90 | $141K | Form 4 |
| Apr 1, 2026 | Andrew Reardon | CLO & Secretary | Sale plan | 963 | $203.22 | $196K | Form 4 |
Latest 100 of 151 trades in the last 12 months.
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Octavio Espinoza | Chief Financial Officer | – | $13M | Aug 12, 2026 |
| Andrew Reardon | CLO & Secretary | – | $11.9M | Nov 2, 2026 |
| Jason Haas | Director | – | $3.7M | Aug 12, 2026 |
| Jason Aryeh | Director | – | $3M | Nov 10, 2026 |
| John L Lamattina | Director | – | $1.6M | Jun 10, 2026 |
| John W Kozarich | Director | – | $1.2M | Nov 12, 2026 |
| Stephen L Sabba | Director | – | $1.2M | Jun 16, 2026 |
| Martine Zimmermann | Director | – | $978K | Nov 12, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
LGND short interest
High short interest. 12.3% of LGND shares are sold short: about 1 share in 8. Over the last 12 reports the number of shares short went up 64%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 2.46M LGND shares were sold short, 12.3% of the shares outstanding, down 1.5% from the report before. At the average daily volume of 234,088 shares, buying them all back would take about 10.5 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 2.46M | 12.32% | -2% | 234,088 | 10.5 |
| Oct 15, 2026 | 2.50M | 12.55% | -7% | 237,677 | 10.5 |
| Sep 30, 2026 | 2.68M | 13.43% | +2% | 306,650 | 8.7 |
| Sep 15, 2026 | 2.63M | 13.20% | +6% | 194,509 | 13.5 |
| Aug 31, 2026 | 2.48M | 12.44% | +1% | 175,764 | 14.1 |
| Aug 14, 2026 | 2.45M | 12.28% | +13% | 279,423 | 8.8 |
| Jul 31, 2026 | 2.17M | 10.83% | +13% | 294,587 | 7.4 |
| Jul 15, 2026 | 1.92M | 9.57% | -10% | 384,586 | 5.0 |
| Jun 30, 2026 | 2.12M | 10.59% | +26% | 814,837 | 2.6 |
| Jun 15, 2026 | 1.69M | 8.43% | +3% | 202,905 | 8.3 |
| May 29, 2026 | 1.64M | 8.18% | +9% | 200,370 | 8.2 |
| May 15, 2026 | 1.51M | 7.51% | +3% | 225,682 | 6.7 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Members of Congress who traded LGND
Since Nov 17, 2024, 1 member of Congress reported 4 purchases and 0 sales of LGND. The latest was a purchase by Gilbert Ray Cisneros, Jr. on May 29, 2026, reported Jun 8, 2026.
Purchases 4Sales 0
Reported trades
| Trade date | Member | Type | Amount | Owner | Reported | Source |
|---|---|---|---|---|---|---|
| May 29, 2026 | Gilbert Ray Cisneros, Jr. (D-CA) | Purchase | $1K–$15K | Self | Jun 8, 2026 | Report |
| Mar 3, 2026 | Gilbert Ray Cisneros, Jr. (D-CA) | Purchase | $1K–$15K | Self | Apr 7, 2026 | Report |
| Jan 15, 2026 | Gilbert Ray Cisneros, Jr. (D-CA) | Purchase | $1K–$15K | Self | Feb 13, 2026 | Report |
| Jan 5, 2026 | Gilbert Ray Cisneros, Jr. (D-CA) | Purchase | $1K–$15K | Self | Feb 13, 2026 | Report |
Source: Periodic Transaction Reports filed with the Clerk of the House and the Secretary of the Senate under the STOCK Act. Members report each trade within 45 days, as a dollar range, not an exact amount. Trades by a spouse or dependent child are included and marked. Paper filings (scanned images) are not included, and Senate reports are shown for current senators only. Links to Senate reports open the Senate’s own site, which shows its terms first and can only be reached from the United States. How these reports work
Ligand Pharmaceuticals company events
Ligand Pharmaceuticals filed 14 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Oct 29, 2026.
- Oct 29, 2026ResultsReleased financial results. Filing
- Sep 24, 2026AnnouncementShared information with investors. Filing
- Sep 22, 2026AnnouncementShared information with investors. Filing
- Aug 6, 2026ResultsReleased financial results. Filing
- Jul 14, 2026DealThe information contained in the first paragraph of item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 2.01. Filing
- Jun 25, 2026AgreementLigand Pharmaceuticals Incorporated completed its previously announced private offering of $700.0 million of 0.00% Convertible Senior Notes due 2031, including the exercise in full of the initial purchasers’ option to purchase up to an additional $75.0 million of Notes. Filing
- Jun 22, 2026AgreementIn connection with the Offering (as defined below), on June 22, 2026, Ligand Pharmaceuticals Incorporated, as borrower, entered into a Consent and Fourth Amendment to Credit Agreement with certain of the Company’s subsidiaries, as Guarantors (as defined therein), the Lenders (as defined therein)… Filing
- Jun 9, 2026LeadershipThe 2026 Annual Meeting of the Stockholders of Ligand Pharmaceuticals Incorporated was held on June 5, 2026. Filing
- May 18, 2026AgreementAs previously disclosed, on April 27, 2026, Ligand Pharmaceuticals Incorporated, a Delaware corporation, entered into an Agreement and Plan of Merger, by and among Ligand, XOMA Royalty Corporation, a Nevada corporation, and Flex Merger Sub, Inc., a Nevada corporation and wholly-owned subsidiary of… Filing
- May 7, 2026ResultsReleased financial results. Filing
- Apr 30, 2026AgreementEnded an important agreement. Filing
- Apr 27, 2026AgreementLigand Pharmaceuticals Incorporated, a Delaware corporation, entered into an Agreement and Plan of Merger, by and among Ligand, XOMA Royalty Corporation, a Nevada corporation, and Flex Merger Sub, Inc., a Nevada corporation and wholly-owned subsidiary of Ligand, pursuant to which, and upon the… Filing
- Feb 26, 2026ResultsReleased financial results. Filing
- Dec 18, 2025AnnouncementShared information with investors. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Ligand Pharmaceuticals financials
Famous investors that hold LGND
5 of the 50 well-known investors we track reported holding LGND in their latest 13F filing. The largest position is Ken Fisher's, worth $40.2M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Fisher · Fisher Asset Management | Q3 2026 | 128,643 | $40.2M | 0.0% | +6% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 33,304 | $10.4M | 0.0% | New |
| Ray Dalio · Bridgewater Associates | Q3 2026 | 9,763 | $3M | 0.0% | New |
| Jim Simons · Renaissance Technologies | Q3 2026 | 7,094 | $2.2M | 0.0% | New |
| Israel Englander · Millennium Management | Q3 2026 | 1,336 | $417K | 0.0% | -66% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named LGND in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | JANUS HENDERSON GROUP Ltd. | 13G/A | 4.6% |
| Nov 16, 2026 | JANUS HENDERSON GROUP Ltd. | 13G/A | 4.6% |
| Nov 10, 2026 | Invesco Ltd. | 13G/A | 7.6% |
| Nov 10, 2026 | Invesco Ltd. | 13G/A | 7.6% |
Questions about Ligand Pharmaceuticals Inc (LGND) stock
Who owns the most LGND stock?
The largest reported owner of Ligand Pharmaceuticals Inc (LGND) is BlackRock, Inc., with 15.5% of the company. In total, 414 funds and institutions reported holding LGND at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are LGND insiders buying or selling?
In the last 12 months, LGND insiders reported no open-market purchases and 151 sales worth $36.5M. The latest trade was on Nov 12, 2026. See every trade.
What is the short interest in LGND?
As of Oct 30, 2026, 2.46M LGND shares were sold short, 12.3% of the shares outstanding, down 1.5% from the report before. At the average daily volume of 234,088 shares, buying them all back would take about 10.5 trading days (days to cover). See the history.
Have members of Congress traded LGND?
Yes. 1 member of Congress reported 4 purchases and 0 sales of LGND since Nov 17, 2024. The latest was reported on Jun 8, 2026. See the trades.
Which famous investors hold LGND?
5 of the 50 well-known investors we track reported LGND in their latest 13F filing, including Ken Fisher, Ken Griffin, Ray Dalio. The largest position is worth $40.2M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.